Epalrestat is a carboxylic acid derivative and a noncompetitive and reversible aldose reductase inhibitor used for the treatment of diabetic neuropathy, which is one of the most common long-term complications in patients with diabetes mellitus. It reduces the accumulation of intracellular sorbitol which is believed to be the cause of diabetic neuropathy, retinopathy and nephropathy It is well tolerated, with the most commonly reported adverse effects being gastrointestinal issues such as nausea and vomiting, as well as increases in certain liver enzymes. Chemically, epalrestat is unusual in th
{{Chembox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 406013101 | ImageFile = Epalrestat.svg | ImageClass = skin-invert-image | ImageSize = 222 | PIN = {(5Z)-5-[(2E)-2-Methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl}acetic acid | OtherNames =
|Section1 =
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).